The present study and future follow-up reports could highlight the benefits of a greater attention to weak/focal p16+ cases, improving the knowledge of rarer hrHPV genotypes, with a positive impact on cervical cancer screening programs. This evidence concerns the gene CDKN2A and cervical carcinoma.